JP2016531567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016531567A5 JP2016531567A5 JP2016531761A JP2016531761A JP2016531567A5 JP 2016531567 A5 JP2016531567 A5 JP 2016531567A5 JP 2016531761 A JP2016531761 A JP 2016531761A JP 2016531761 A JP2016531761 A JP 2016531761A JP 2016531567 A5 JP2016531567 A5 JP 2016531567A5
- Authority
- JP
- Japan
- Prior art keywords
- domain
- fusion protein
- derivative
- multimerization
- multimerization domain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000037865 fusion proteins Human genes 0.000 claims description 236
- 108020001507 fusion proteins Proteins 0.000 claims description 236
- 210000004027 cell Anatomy 0.000 claims description 153
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 125
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 114
- 229920001184 polypeptide Polymers 0.000 claims description 112
- 108020004707 nucleic acids Proteins 0.000 claims description 70
- 102000039446 nucleic acids Human genes 0.000 claims description 70
- 150000007523 nucleic acids Chemical class 0.000 claims description 70
- 238000004132 cross linking Methods 0.000 claims description 59
- 108010027179 Tacrolimus Binding Proteins Proteins 0.000 claims description 56
- 102000018679 Tacrolimus Binding Proteins Human genes 0.000 claims description 56
- -1 lidahololimus Chemical compound 0.000 claims description 56
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 36
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 36
- 229960002930 sirolimus Drugs 0.000 claims description 36
- 102000005962 receptors Human genes 0.000 claims description 34
- 108020003175 receptors Proteins 0.000 claims description 34
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 claims description 32
- 230000000139 costimulatory effect Effects 0.000 claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 29
- 201000010099 disease Diseases 0.000 claims description 28
- 230000003463 hyperproliferative effect Effects 0.000 claims description 28
- 230000004927 fusion Effects 0.000 claims description 27
- 208000023275 Autoimmune disease Diseases 0.000 claims description 26
- 208000027866 inflammatory disease Diseases 0.000 claims description 26
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 25
- 208000024908 graft versus host disease Diseases 0.000 claims description 25
- 102100038080 B-cell receptor CD22 Human genes 0.000 claims description 24
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 24
- 229930105110 Cyclosporin A Natural products 0.000 claims description 24
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 24
- 108010036949 Cyclosporine Proteins 0.000 claims description 24
- 229930191978 Gibberellin Natural products 0.000 claims description 24
- 101000884305 Homo sapiens B-cell receptor CD22 Proteins 0.000 claims description 24
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 24
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 24
- WTIJXIZOODAMJT-WBACWINTSA-N [(3r,4s,5r,6s)-5-hydroxy-6-[4-hydroxy-3-[[5-[[4-hydroxy-7-[(2s,3r,4s,5r)-3-hydroxy-5-methoxy-6,6-dimethyl-4-(5-methyl-1h-pyrrole-2-carbonyl)oxyoxan-2-yl]oxy-8-methyl-2-oxochromen-3-yl]carbamoyl]-4-methyl-1h-pyrrole-3-carbonyl]amino]-8-methyl-2-oxochromen- Chemical compound O([C@@H]1[C@H](C(O[C@H](OC=2C(=C3OC(=O)C(NC(=O)C=4C(=C(C(=O)NC=5C(OC6=C(C)C(O[C@@H]7[C@@H]([C@H](OC(=O)C=8NC(C)=CC=8)[C@@H](OC)C(C)(C)O7)O)=CC=C6C=5O)=O)NC=4)C)=C(O)C3=CC=2)C)[C@@H]1O)(C)C)OC)C(=O)C1=CC=C(C)N1 WTIJXIZOODAMJT-WBACWINTSA-N 0.000 claims description 24
- 229960001265 ciclosporin Drugs 0.000 claims description 24
- 229950001513 coumamycin Drugs 0.000 claims description 24
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 claims description 24
- 239000003448 gibberellin Substances 0.000 claims description 24
- 229960000485 methotrexate Drugs 0.000 claims description 24
- 102000004169 proteins and genes Human genes 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 23
- 206010028980 Neoplasm Diseases 0.000 claims description 22
- 239000000427 antigen Substances 0.000 claims description 22
- 108091007433 antigens Proteins 0.000 claims description 22
- 102000036639 antigens Human genes 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 22
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 239000003446 ligand Substances 0.000 claims description 20
- CKUAMXWZIHXZJC-LOSJGSFVSA-N 2-[3-[(1r)-3-(3,4-dimethoxyphenyl)-1-[(2s)-1-(3,3-dimethyl-2-oxopentanoyl)piperidine-2-carbonyl]oxypropyl]phenoxy]acetic acid Chemical compound CCC(C)(C)C(=O)C(=O)N1CCCC[C@H]1C(=O)O[C@@H](C=1C=C(OCC(O)=O)C=CC=1)CCC1=CC=C(OC)C(OC)=C1 CKUAMXWZIHXZJC-LOSJGSFVSA-N 0.000 claims description 18
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 16
- 102000004631 Calcineurin Human genes 0.000 claims description 16
- 108010042955 Calcineurin Proteins 0.000 claims description 16
- 102000001493 Cyclophilins Human genes 0.000 claims description 16
- 108010068682 Cyclophilins Proteins 0.000 claims description 16
- 102000010956 Glypican Human genes 0.000 claims description 16
- 108050001154 Glypican Proteins 0.000 claims description 16
- 108050007237 Glypican-3 Proteins 0.000 claims description 16
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 16
- 101000777628 Homo sapiens Leukocyte antigen CD37 Proteins 0.000 claims description 16
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 claims description 16
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 claims description 16
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 claims description 16
- 102100031586 Leukocyte antigen CD37 Human genes 0.000 claims description 16
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 claims description 16
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 claims description 16
- 102100024964 Neural cell adhesion molecule L1 Human genes 0.000 claims description 16
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 claims description 16
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 16
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 claims description 16
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims description 16
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims description 16
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims description 16
- 206010066476 Haematological malignancy Diseases 0.000 claims description 14
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 14
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims description 14
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims description 14
- 230000001086 cytosolic effect Effects 0.000 claims description 14
- 230000002209 hydrophobic effect Effects 0.000 claims description 14
- 210000004698 lymphocyte Anatomy 0.000 claims description 14
- 230000011664 signaling Effects 0.000 claims description 14
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 12
- ZHYGVVKSAGDVDY-QQQXYHJWSA-N 7-o-demethyl cypher Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](O)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 ZHYGVVKSAGDVDY-QQQXYHJWSA-N 0.000 claims description 12
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims description 12
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims description 12
- 102100024746 Dihydrofolate reductase Human genes 0.000 claims description 12
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims description 12
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 12
- 102100027913 Peptidyl-prolyl cis-trans isomerase FKBP1A Human genes 0.000 claims description 12
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 12
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims description 12
- 108010006877 Tacrolimus Binding Protein 1A Proteins 0.000 claims description 12
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 12
- 239000000556 agonist Substances 0.000 claims description 12
- 108020001096 dihydrofolate reductase Proteins 0.000 claims description 12
- 229960005167 everolimus Drugs 0.000 claims description 12
- KASDHRXLYQOAKZ-ZPSXYTITSA-N pimecrolimus Chemical compound C/C([C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H](C(C[C@H](O)[C@H]1C)=O)CC)=C\[C@@H]1CC[C@@H](Cl)[C@H](OC)C1 KASDHRXLYQOAKZ-ZPSXYTITSA-N 0.000 claims description 12
- 229960005330 pimecrolimus Drugs 0.000 claims description 12
- 229960001967 tacrolimus Drugs 0.000 claims description 12
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims description 12
- 229960000235 temsirolimus Drugs 0.000 claims description 12
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 12
- YYSFXUWWPNHNAZ-PKJQJFMNSA-N umirolimus Chemical compound C1[C@@H](OC)[C@H](OCCOCC)CC[C@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 YYSFXUWWPNHNAZ-PKJQJFMNSA-N 0.000 claims description 12
- 229950007775 umirolimus Drugs 0.000 claims description 12
- CGTADGCBEXYWNE-JUKNQOCSSA-N zotarolimus Chemical compound N1([C@H]2CC[C@@H](C[C@@H](C)[C@H]3OC(=O)[C@@H]4CCCCN4C(=O)C(=O)[C@@]4(O)[C@H](C)CC[C@H](O4)C[C@@H](/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C3)OC)C[C@H]2OC)C=NN=N1 CGTADGCBEXYWNE-JUKNQOCSSA-N 0.000 claims description 12
- 229950009819 zotarolimus Drugs 0.000 claims description 12
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 claims description 10
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 10
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 10
- 239000013604 expression vector Substances 0.000 claims description 10
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 10
- 102000034285 signal transducing proteins Human genes 0.000 claims description 10
- 108091006024 signal transducing proteins Proteins 0.000 claims description 10
- 230000004913 activation Effects 0.000 claims description 9
- JLIDBLDQVAYHNE-LXGGSRJLSA-N 2-cis-abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\C1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-LXGGSRJLSA-N 0.000 claims description 8
- 102100028247 Abl interactor 1 Human genes 0.000 claims description 8
- 101100300093 Arabidopsis thaliana PYL1 gene Proteins 0.000 claims description 8
- 102100027205 B-cell antigen receptor complex-associated protein alpha chain Human genes 0.000 claims description 8
- 102100027203 B-cell antigen receptor complex-associated protein beta chain Human genes 0.000 claims description 8
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 claims description 8
- 108700012439 CA9 Proteins 0.000 claims description 8
- 102100027207 CD27 antigen Human genes 0.000 claims description 8
- 102100038078 CD276 antigen Human genes 0.000 claims description 8
- 101710185679 CD276 antigen Proteins 0.000 claims description 8
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims description 8
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 claims description 8
- 101150013553 CD40 gene Proteins 0.000 claims description 8
- 102100032912 CD44 antigen Human genes 0.000 claims description 8
- 108010058905 CD44v6 antigen Proteins 0.000 claims description 8
- 102100025221 CD70 antigen Human genes 0.000 claims description 8
- 102100025570 Cancer/testis antigen 1 Human genes 0.000 claims description 8
- 102100024423 Carbonic anhydrase 9 Human genes 0.000 claims description 8
- 102100024965 Caspase recruitment domain-containing protein 11 Human genes 0.000 claims description 8
- 108010009685 Cholinergic Receptors Proteins 0.000 claims description 8
- 102100028757 Chondroitin sulfate proteoglycan 4 Human genes 0.000 claims description 8
- 101100503636 Danio rerio fyna gene Proteins 0.000 claims description 8
- 102100033553 Delta-like protein 4 Human genes 0.000 claims description 8
- 102000012804 EPCAM Human genes 0.000 claims description 8
- 101150084967 EPCAM gene Proteins 0.000 claims description 8
- 108010055196 EphA2 Receptor Proteins 0.000 claims description 8
- 102100030340 Ephrin type-A receptor 2 Human genes 0.000 claims description 8
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims description 8
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims description 8
- 102100031940 Epithelial cell adhesion molecule Human genes 0.000 claims description 8
- 101150018272 FYN gene Proteins 0.000 claims description 8
- 101710088083 Glomulin Proteins 0.000 claims description 8
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 claims description 8
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 claims description 8
- 101000724225 Homo sapiens Abl interactor 1 Proteins 0.000 claims description 8
- 101000914489 Homo sapiens B-cell antigen receptor complex-associated protein alpha chain Proteins 0.000 claims description 8
- 101000914491 Homo sapiens B-cell antigen receptor complex-associated protein beta chain Proteins 0.000 claims description 8
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims description 8
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims description 8
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims description 8
- 101000856237 Homo sapiens Cancer/testis antigen 1 Proteins 0.000 claims description 8
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 8
- 101000914321 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 7 Proteins 0.000 claims description 8
- 101000761179 Homo sapiens Caspase recruitment domain-containing protein 11 Proteins 0.000 claims description 8
- 101000916489 Homo sapiens Chondroitin sulfate proteoglycan 4 Proteins 0.000 claims description 8
- 101000872077 Homo sapiens Delta-like protein 4 Proteins 0.000 claims description 8
- 101000920667 Homo sapiens Epithelial cell adhesion molecule Proteins 0.000 claims description 8
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 claims description 8
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 claims description 8
- 101001103039 Homo sapiens Inactive tyrosine-protein kinase transmembrane receptor ROR1 Proteins 0.000 claims description 8
- 101000998120 Homo sapiens Interleukin-3 receptor subunit alpha Proteins 0.000 claims description 8
- 101001047640 Homo sapiens Linker for activation of T-cells family member 1 Proteins 0.000 claims description 8
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 8
- 101001051490 Homo sapiens Neural cell adhesion molecule L1 Proteins 0.000 claims description 8
- 101001103036 Homo sapiens Nuclear receptor ROR-alpha Proteins 0.000 claims description 8
- 101000617725 Homo sapiens Pregnancy-specific beta-1-glycoprotein 2 Proteins 0.000 claims description 8
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 claims description 8
- 101000702132 Homo sapiens Protein spinster homolog 1 Proteins 0.000 claims description 8
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims description 8
- 101000946860 Homo sapiens T-cell surface glycoprotein CD3 epsilon chain Proteins 0.000 claims description 8
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims description 8
- 102100039615 Inactive tyrosine-protein kinase transmembrane receptor ROR1 Human genes 0.000 claims description 8
- 102100020793 Interleukin-13 receptor subunit alpha-2 Human genes 0.000 claims description 8
- 101710112634 Interleukin-13 receptor subunit alpha-2 Proteins 0.000 claims description 8
- 102100033493 Interleukin-3 receptor subunit alpha Human genes 0.000 claims description 8
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 8
- 102000017578 LAG3 Human genes 0.000 claims description 8
- 101150028321 Lck gene Proteins 0.000 claims description 8
- 102100024032 Linker for activation of T-cells family member 1 Human genes 0.000 claims description 8
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 8
- 102000003735 Mesothelin Human genes 0.000 claims description 8
- 108090000015 Mesothelin Proteins 0.000 claims description 8
- 101100268066 Mus musculus Zap70 gene Proteins 0.000 claims description 8
- 102100029527 Natural cytotoxicity triggering receptor 3 ligand 1 Human genes 0.000 claims description 8
- 101710201161 Natural cytotoxicity triggering receptor 3 ligand 1 Proteins 0.000 claims description 8
- 108010012255 Neural Cell Adhesion Molecule L1 Proteins 0.000 claims description 8
- 108010069196 Neural Cell Adhesion Molecules Proteins 0.000 claims description 8
- 102000001068 Neural Cell Adhesion Molecules Human genes 0.000 claims description 8
- 101100300089 Oryza sativa subsp. japonica PYL10 gene Proteins 0.000 claims description 8
- 102000036673 PRAME Human genes 0.000 claims description 8
- 108060006580 PRAME Proteins 0.000 claims description 8
- 102100022019 Pregnancy-specific beta-1-glycoprotein 2 Human genes 0.000 claims description 8
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 claims description 8
- 102100036735 Prostate stem cell antigen Human genes 0.000 claims description 8
- 108010074687 Signaling Lymphocytic Activation Molecule Family Member 1 Proteins 0.000 claims description 8
- 102100029215 Signaling lymphocytic activation molecule Human genes 0.000 claims description 8
- 108010002687 Survivin Proteins 0.000 claims description 8
- 102100035721 Syndecan-1 Human genes 0.000 claims description 8
- 102100035794 T-cell surface glycoprotein CD3 epsilon chain Human genes 0.000 claims description 8
- 101150057140 TACSTD1 gene Proteins 0.000 claims description 8
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims description 8
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 8
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims description 8
- 101001038499 Yarrowia lipolytica (strain CLIB 122 / E 150) Lysine acetyltransferase Proteins 0.000 claims description 8
- 102000034337 acetylcholine receptors Human genes 0.000 claims description 8
- 150000001413 amino acids Chemical group 0.000 claims description 8
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 claims description 8
- 230000001605 fetal effect Effects 0.000 claims description 8
- 229940014144 folate Drugs 0.000 claims description 8
- 239000011724 folic acid Substances 0.000 claims description 8
- 102000006495 integrins Human genes 0.000 claims description 8
- 108010044426 integrins Proteins 0.000 claims description 8
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 claims description 8
- 101150047061 tag-72 gene Proteins 0.000 claims description 8
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 8
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 claims description 7
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims description 7
- 102100034256 Mucin-1 Human genes 0.000 claims description 7
- 102100023123 Mucin-16 Human genes 0.000 claims description 7
- 108091033319 polynucleotide Proteins 0.000 claims description 7
- 102000040430 polynucleotide Human genes 0.000 claims description 7
- 239000002157 polynucleotide Substances 0.000 claims description 7
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 6
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 6
- 108091008874 T cell receptors Proteins 0.000 claims description 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 230000036210 malignancy Effects 0.000 claims description 6
- 230000001737 promoting effect Effects 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 230000001105 regulatory effect Effects 0.000 claims description 5
- 108010054814 DNA Gyrase Proteins 0.000 claims description 4
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 4
- 230000006044 T cell activation Effects 0.000 claims description 4
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 4
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 4
- 239000003112 inhibitor Substances 0.000 claims description 4
- 102100031780 Endonuclease Human genes 0.000 claims description 2
- 108010042407 Endonucleases Proteins 0.000 claims description 2
- 239000003431 cross linking reagent Substances 0.000 claims description 2
- 239000000409 cytokine receptor agonist Substances 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 238000000034 method Methods 0.000 description 61
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 2
- 229940121354 immunomodulator Drugs 0.000 description 2
- 230000002584 immunomodulator Effects 0.000 description 2
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361859697P | 2013-07-29 | 2013-07-29 | |
| US61/859,697 | 2013-07-29 | ||
| US201461934092P | 2014-01-31 | 2014-01-31 | |
| US61/934,092 | 2014-01-31 | ||
| PCT/US2014/047852 WO2015017214A1 (en) | 2013-07-29 | 2014-07-23 | Multipartite signaling proteins and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019112035A Division JP2019146598A (ja) | 2013-07-29 | 2019-06-17 | 多部分シグナル伝達タンパク質およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016531567A JP2016531567A (ja) | 2016-10-13 |
| JP2016531567A5 true JP2016531567A5 (enExample) | 2017-08-31 |
| JP6543626B2 JP6543626B2 (ja) | 2019-07-10 |
Family
ID=52432340
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016531761A Active JP6543626B2 (ja) | 2013-07-29 | 2014-07-23 | 多部分シグナル伝達タンパク質およびその使用 |
| JP2019112035A Withdrawn JP2019146598A (ja) | 2013-07-29 | 2019-06-17 | 多部分シグナル伝達タンパク質およびその使用 |
| JP2020092158A Active JP6748796B1 (ja) | 2013-07-29 | 2020-05-27 | 多部分シグナル伝達タンパク質およびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019112035A Withdrawn JP2019146598A (ja) | 2013-07-29 | 2019-06-17 | 多部分シグナル伝達タンパク質およびその使用 |
| JP2020092158A Active JP6748796B1 (ja) | 2013-07-29 | 2020-05-27 | 多部分シグナル伝達タンパク質およびその使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (6) | US10196444B2 (enExample) |
| EP (2) | EP3925618A1 (enExample) |
| JP (3) | JP6543626B2 (enExample) |
| AU (2) | AU2014296626B2 (enExample) |
| CA (1) | CA2956667A1 (enExample) |
| DK (1) | DK3027204T3 (enExample) |
| ES (1) | ES2910004T3 (enExample) |
| WO (1) | WO2015017214A1 (enExample) |
Families Citing this family (109)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9944700B2 (en) | 2013-03-13 | 2018-04-17 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
| EP2970426B1 (en) | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| EP3087101B1 (en) * | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| AU2014368383B2 (en) * | 2013-12-20 | 2020-01-16 | Cellectis | Method of engineering multi-input signal sensitive T cell for immunotherapy |
| ES2792849T3 (es) | 2014-02-10 | 2020-11-12 | Univ Emory | Expresión de polipéptido químico con receptores de linfocitos variables en células inmunes y usos para tratar el cáncer |
| GB201506423D0 (en) | 2015-04-15 | 2015-05-27 | Tc Biopharm Ltd | Gamma delta T cells and uses thereof |
| ES2692206T3 (es) | 2014-11-26 | 2018-11-30 | Miltenyi Biotec Gmbh | Inmunoterapia combinada de receptores de reconocimiento de antígenos y células hematopoyéticas para el tratamiento de enfermedades |
| GB201507368D0 (en) | 2015-04-30 | 2015-06-17 | Ucl Business Plc | Cell |
| US11173179B2 (en) * | 2015-06-25 | 2021-11-16 | Icell Gene Therapeutics Llc | Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof |
| KR20250134209A (ko) | 2015-11-23 | 2025-09-09 | 트르스티스 오브 보스톤 유니버시티 | 키메라 항원 수용체에 관한 방법 및 조성물 |
| EP3390434A2 (en) * | 2015-12-14 | 2018-10-24 | Bellicum Pharmaceuticals, Inc. | Dual controls for therapeutic cell activation or elimination |
| EP3184548A1 (en) | 2015-12-23 | 2017-06-28 | Miltenyi Biotec GmbH | Chimeric antigen receptor with cytokine receptor activating or blocking domain |
| EP3413896B1 (en) | 2016-02-12 | 2021-03-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| CA3014078A1 (en) | 2016-02-12 | 2017-08-17 | Bluebird Bio, Inc. | Vcn enhancer compositions and methods of using the same |
| US10871490B2 (en) | 2016-02-29 | 2020-12-22 | Multenyi Biotec, gmbH | Assay for detection of chimeric antigen receptor T cells |
| PL3436079T3 (pl) | 2016-04-01 | 2021-12-20 | Kite Pharma, Inc. | Antygen chimeryczny i receptory komórek t oraz sposoby ich stosowania |
| PE20190201A1 (es) | 2016-04-01 | 2019-02-05 | Amgen Inc | Receptores quimericos de flt3 y metodos de uso de los mismos |
| US10689450B2 (en) | 2016-04-01 | 2020-06-23 | Kite Pharma, Inc | BCMA binding molecules and methods of use thereof |
| PE20190356A1 (es) | 2016-04-01 | 2019-03-07 | Kite Pharma Inc | Receptores quimericos y metodos de uso de los mismos |
| JP2019510786A (ja) | 2016-04-05 | 2019-04-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 免疫療法におけるＴＧＦβの阻害 |
| JP7125351B2 (ja) * | 2016-04-14 | 2022-08-24 | ２セブンティ バイオ インコーポレイテッド | サルベージキメラ抗原受容体システム |
| CA3034094A1 (en) | 2016-08-16 | 2018-02-22 | Bluebird Bio, Inc. | Il-10 receptor alpha homing endonuclease variants, compositions, and methods of use |
| US20190262398A1 (en) | 2016-08-23 | 2019-08-29 | Bluebird Bio, Inc. | Tim3 homing endonuclease variants, compositions, and methods of use |
| IL265045B2 (en) * | 2016-09-08 | 2023-09-01 | Bluebird Bio Inc | Variants of endonuclease pd-1, compositions and methods of use |
| AU2017346683B2 (en) | 2016-10-17 | 2024-04-18 | Regeneron Pharmaceuticals, Inc. | TGFβR2 endonuclease variants, compositions, and methods of use |
| ES2916335T3 (es) * | 2016-10-20 | 2022-06-30 | Celgene Corp | Receptores de antígeno quimérico heterodimerizable basados en cereblon |
| EP3541833B1 (en) | 2016-11-17 | 2024-01-24 | 2seventy bio, Inc. | Tgf beta signal convertor |
| AU2017368050A1 (en) | 2016-11-29 | 2019-06-20 | Puretech Lyt, Inc. | Exosomes for delivery of therapeutic agents |
| JP7206214B2 (ja) | 2016-12-13 | 2023-01-17 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法 |
| AU2018221730B2 (en) | 2017-02-15 | 2024-06-20 | Novo Nordisk A/S | Donor repair templates multiplex genome editing |
| JOP20180027A1 (ar) | 2017-03-28 | 2019-01-30 | Cell Design Labs Inc | بوليبيبتيدات مخلطة و طرق لتغيير موضع الغشاء فيها |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| WO2018200585A1 (en) * | 2017-04-26 | 2018-11-01 | Eureka Therapeutics, Inc. | Cells expressing chimeric antigen receptors and secondary effectors and uses thereof |
| EP3634437A4 (en) * | 2017-05-19 | 2020-11-18 | Case Western Reserve University | COMPOSITIONS AND METHODS FOR EX VIVO EXPANSION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC USES |
| AU2018270515A1 (en) * | 2017-05-19 | 2019-12-05 | The Regents Of The University Of California | Antibody chemically induced dimerizer (abCID) as molecular switches for regulating cellular therapies |
| SG11202000555UA (en) | 2017-06-21 | 2020-02-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors (cars), compositions and methods thereof |
| TW201908335A (zh) * | 2017-07-25 | 2019-03-01 | 美國德州系統大學評議委員會 | 增強之嵌合抗原受體及其用途 |
| US11786557B2 (en) | 2017-10-02 | 2023-10-17 | Fred Hutchinson Cancer Center | Luteinizing hormone receptor binding agents and luteinizing hormone agonists to identify, expand, ablate and modify stem cells |
| US11390655B2 (en) | 2017-11-16 | 2022-07-19 | Kite Pharma, Inc. | Modified chimeric antigen receptors and methods of use |
| EP3723787A4 (en) * | 2017-12-14 | 2021-09-01 | Bluebird Bio, Inc. | DARIC INTERLEUKIN RECEPTORS |
| RU2020122708A (ru) * | 2017-12-14 | 2022-01-14 | 2севэнти био, Инк. | Рецепторы nkg2d daric |
| JP2021506329A (ja) | 2017-12-20 | 2021-02-22 | ザンクト アンナ キンダークレプスフォルシュング | リガンド制御したタンパク質−タンパク質相互作用システム |
| EP3502130A1 (en) | 2017-12-20 | 2019-06-26 | St. Anna Kinderkrebsforschung | Ligand regulated protein-protein interaction system |
| US11965191B2 (en) | 2018-01-18 | 2024-04-23 | California Institute Of Technology | Programmable protein circuits in living cells |
| WO2019195586A1 (en) | 2018-04-06 | 2019-10-10 | The Regents Of The University Of California | Methods of treating egfrviii expressing glioblastomas |
| US12090170B2 (en) | 2018-04-06 | 2024-09-17 | The Regents Of The University Of California | Methods of treating glioblastomas |
| UY38182A (es) | 2018-04-10 | 2019-10-31 | Amgen Inc | Receptores quiméricos de dll3 y métodos para su uso |
| BR112020020887A2 (pt) | 2018-04-12 | 2021-04-06 | Umoja Biopharma, Inc | Vetores virais e linhagens celulares de empacotamento |
| JP7584127B2 (ja) * | 2018-04-26 | 2024-11-15 | ベイラー カレッジ オブ メディスン | 活性化された病原性ｔ細胞およびｎｋ細胞の選択的標的化のための自己／同種免疫防御受容体 |
| CA3091490A1 (en) | 2018-04-27 | 2019-10-31 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Rapamycin resistant cells |
| WO2020018695A1 (en) | 2018-07-18 | 2020-01-23 | Amgen Inc. | Chimeric receptors to steap1 and methods of use thereof |
| EP3833742A2 (en) | 2018-08-09 | 2021-06-16 | Juno Therapeutics, Inc. | Processes for generating engineered cells and compositions thereof |
| US11542305B2 (en) | 2018-08-31 | 2023-01-03 | California Institute Of Technology | Synthetic protein circuits detecting signal transducer activity |
| KR20210102925A (ko) | 2018-12-10 | 2021-08-20 | 블루버드 바이오, 인코포레이티드. | 호밍 엔도뉴클레아제 변이체 |
| IL283734B2 (en) | 2018-12-12 | 2025-03-01 | Kite Pharma Inc | Chimeric antigen receptors and CAR-T cells and methods of use |
| WO2020123947A1 (en) * | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| WO2020123938A1 (en) * | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| AU2019397152A1 (en) * | 2018-12-14 | 2021-06-24 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| WO2020123933A1 (en) * | 2018-12-14 | 2020-06-18 | Bluebird Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| EP3908653A4 (en) | 2019-01-10 | 2022-11-02 | California Institute of Technology | A synthetic system for tunable thresholding of protein signals |
| KR20210138574A (ko) | 2019-03-01 | 2021-11-19 | 알로젠 테라퓨틱스 인코포레이티드 | Dll3 표적화 키메라 항원 수용체 및 결합제 |
| CN113710697A (zh) * | 2019-03-15 | 2021-11-26 | 美国政府(由卫生和人类服务部的部长所代表) | 嵌合衔接子和激酶信号传导蛋白及其在免疫疗法中的用途 |
| WO2020219848A1 (en) | 2019-04-26 | 2020-10-29 | Allogene Therapeutics, Inc. | Rituximab-resistant chimeric antigen receptors and uses thereof |
| WO2020219812A1 (en) | 2019-04-26 | 2020-10-29 | Allogene Therapeutics, Inc. | Methods of manufacturing allogeneic car t cells |
| KR20220016474A (ko) | 2019-05-01 | 2022-02-09 | 주노 쎄러퓨티크스 인코퍼레이티드 | 변형된 ｃｄ247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법 |
| BR112021021075A2 (pt) | 2019-05-01 | 2021-12-14 | Editas Medicine Inc | Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos |
| US11434297B2 (en) | 2019-05-04 | 2022-09-06 | Inhibrx, Inc. | CD123-binding polypeptides and uses thereof |
| BR112021021048A2 (pt) | 2019-05-04 | 2021-12-14 | Inhibrx Inc | Polipeptídeos que se ligam a cd33 e seus usos |
| US12043667B2 (en) | 2019-05-04 | 2024-07-23 | Inhibrx Biosciences, Inc. | CLEC12a binding polypeptides and uses thereof |
| CN114206928B (zh) * | 2019-05-08 | 2025-08-08 | 印希彼生物科学公司 | Cd33靶向免疫疗法 |
| CA3148027A1 (en) * | 2019-05-08 | 2020-11-12 | 2Seventy Bio, Inc. | Cll-1 targeted immunotherapies |
| MA55910A (fr) * | 2019-05-08 | 2022-03-16 | 2Seventy Bio Inc | Immunothérapies ciblant cd123 |
| EP3980451A1 (en) * | 2019-06-05 | 2022-04-13 | Yeda Research and Development Co. Ltd | Artificial receptors, recombinant cells comprising thereof, methods for their preparation, and method of using thereof |
| WO2021030153A2 (en) * | 2019-08-09 | 2021-02-18 | A2 Biotherapeutics, Inc. | Engineered t cell receptors and uses thereof |
| WO2021044439A1 (en) * | 2019-09-08 | 2021-03-11 | Immunoadaptive Cell Therapy Pvt Ltd. | Inducible cytokine signals & methods for immunotherapy |
| CA3155027A1 (en) * | 2019-09-30 | 2021-04-08 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| CN114981441A (zh) | 2019-10-16 | 2022-08-30 | 优莫佳生物制药股份有限公司 | 用于通用受体疗法的逆转录病毒载体 |
| BR112022011399A2 (pt) | 2019-12-11 | 2022-08-30 | A2 Biotherapeutics Inc | Receptor de antígeno quimérico baseado em lilrb1 |
| IL295129A (en) | 2020-01-30 | 2022-09-01 | Umoja Biopharma Inc | Bispecific transduction enhancer |
| US20230133564A1 (en) * | 2020-04-01 | 2023-05-04 | Medigene Immunotherapies Gmbh | Cd3-fusion protein and uses thereof |
| EP3916388A1 (en) | 2020-05-27 | 2021-12-01 | Miltenyi Biotec B.V. & Co. KG | Reagents for detection of chimeric antigen receptor cells |
| EP4171616A1 (en) | 2020-06-26 | 2023-05-03 | Juno Therapeutics GmbH | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
| WO2022015955A1 (en) | 2020-07-16 | 2022-01-20 | Umoja Biopharma, Inc. | Gated adapter targeting receptor |
| GB2607514B (en) | 2020-07-20 | 2023-06-21 | Enanta Pharm Inc | Functionalized peptides as antiviral agents |
| MX2023002104A (es) | 2020-08-20 | 2023-07-10 | A2 Biotherapeutics Inc | Composiciones y métodos para tratar cánceres positivos para egfr. |
| KR20250140123A (ko) | 2020-08-20 | 2025-09-24 | 에이투 바이오쎄라퓨틱스, 인크. | 메소텔린 양성 암을 치료하기 위한 조성물 및 방법 |
| AU2021329375A1 (en) | 2020-08-20 | 2023-04-20 | A2 Biotherapeutics, Inc. | Compositions and methods for treating ceacam positive cancers |
| WO2022099175A1 (en) * | 2020-11-09 | 2022-05-12 | 2Seventy Bio, Inc. | Cd33 targeted immunotherapies |
| CA3199588A1 (en) | 2020-11-20 | 2022-05-27 | Andrew Scharenberg | Vector system for delivery of multiple polynucleotides and uses thereof |
| US11352363B1 (en) | 2020-11-23 | 2022-06-07 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11384090B2 (en) | 2020-11-23 | 2022-07-12 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| CN116829571A (zh) | 2020-11-23 | 2023-09-29 | 英安塔制药有限公司 | 新型螺旋吡咯烷衍生的抗病毒药物 |
| WO2022115492A1 (en) | 2020-11-24 | 2022-06-02 | Lyell Immunopharma, Inc. | Methods for making, compositions comprising, and methods of using rejuvenated t cells |
| JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス，インコーポレイテッド | プロテアーゼ活性化ｃｄ４５ゲートｃａｒ |
| KR102471898B1 (ko) * | 2021-01-25 | 2022-12-06 | 알지노믹스 주식회사 | 면역관문 억제제를 발현하는 암 특이적 트랜스-스플라이싱 리보자임 및 이의 용도 |
| JP7618299B2 (ja) * | 2021-01-25 | 2025-01-21 | アールズィーノミクス・インコーポレイテッド | 免疫チェックポイント阻害剤を発現するがん特異的トランス－スプライシングリボザイム及びこの用途｛ｔｕｍｏｒ－ｔａｒｇｅｔｉｎｇ ｔｒａｎｓ－ｓｐｌｉｃｉｎｇ ｒｉｂｏｚｙｍｅ ｅｘｐｒｅｓｓｉｎｇ ｉｍｍｕｎｅ ｃｈｅｃｋｐｏｉｎｔ ｉｎｈｉｂｉｔｏｒ ａｎｄ ｕｓｅ ｔｈｅｒｅｏｆ｝ |
| CA3206009A1 (en) * | 2021-01-27 | 2022-08-04 | Umoja Biopharma, Inc. | Lentivirus for generating cells expressing anti-cd19 chimeric antigen receptor |
| US12162940B2 (en) | 2021-05-05 | 2024-12-10 | Immatics Biotechnologies Gmbh | BMA031 antigen binding polypeptides |
| US11319325B1 (en) | 2021-05-11 | 2022-05-03 | Enanta Pharmaceuticals, Inc. | Macrocyclic spiropyrrolidine derived antiviral agents |
| US11325916B1 (en) | 2021-07-29 | 2022-05-10 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US11339170B1 (en) | 2021-07-23 | 2022-05-24 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| EP4376876A1 (en) | 2021-07-26 | 2024-06-05 | Kite Pharma, Inc. | Split chimeric antigen receptors and methods of use |
| US12479854B2 (en) | 2021-07-29 | 2025-11-25 | Enanta Pharmaceuticals, Inc. | Spiropyrrolidine derived antiviral agents |
| US20230112648A1 (en) * | 2021-09-17 | 2023-04-13 | Homology Medicines, Inc. | Non-naturally occurring polyadenylation elements and methods of use thereof |
| CN119585438A (zh) | 2022-05-26 | 2025-03-07 | 再生元制药公司 | 用于维持慢病毒载体的组合物及其用途 |
| TW202440623A (zh) | 2022-11-28 | 2024-10-16 | 美商艾洛基因醫療公司 | 靶向密連蛋白１８﹒２之嵌合抗原受體及結合劑以及其用途 |
| WO2024182539A1 (en) | 2023-02-28 | 2024-09-06 | Lyell Immunopharma, Inc. | Methods of culturing reprogrammed cells |
| US20250152743A1 (en) * | 2023-11-13 | 2025-05-15 | California Institute Of Technology | Synpoptosis circuits for programmable cell death control |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1999A (en) | 1841-03-12 | Improvement in seed-planters | ||
| US1995A (en) | 1841-03-03 | Latch of door and other locks | ||
| US6291161B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertiore |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| US5283173A (en) | 1990-01-24 | 1994-02-01 | The Research Foundation Of State University Of New York | System to detect protein-protein interactions |
| WO1993015210A1 (en) * | 1992-01-23 | 1993-08-05 | Merck Patent Gmbh | Monomeric and dimeric antibody-fragment fusion proteins |
| PL310327A1 (en) | 1993-02-12 | 1995-12-11 | Univ Leland Stanford Junior | Adjustable transcription of target genes and other biological processes |
| US6972193B1 (en) | 1993-02-12 | 2005-12-06 | Board Of Trustees Of Leland Stanford Junior University | Regulated transcription of targeted genes and other biological events |
| ES2229236T3 (es) | 1994-01-11 | 2005-04-16 | Dyax Corporation | Inhibidores de la plasmina humana derivados de los dominios de kunitz. |
| US6187757B1 (en) | 1995-06-07 | 2001-02-13 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using novel compounds |
| GB9518220D0 (en) | 1995-09-06 | 1995-11-08 | Medical Res Council | Checkpoint gene |
| AU755784B2 (en) * | 1998-01-15 | 2002-12-19 | Ariad Pharmaceuticals, Inc. | Regulation of biological events using multimeric chimeric proteins |
| CA2319492A1 (en) | 1998-02-13 | 1999-08-19 | President And Fellows Of Harvard College | Novel dimerizing agents, their production and use |
| AUPP221098A0 (en) | 1998-03-06 | 1998-04-02 | Diatech Pty Ltd | V-like domain binding molecules |
| AU2006204459B2 (en) | 2005-01-05 | 2012-11-01 | F-Star Therapeutics Limited | Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions |
| GB0504767D0 (en) | 2005-03-08 | 2005-04-13 | Ares Trading Sa | Lipocalin protein |
| EP1829895A1 (en) | 2006-03-03 | 2007-09-05 | f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. | Bispecific molecule binding TLR9 and CD32 and comprising a T cell epitope for treatment of allergies |
| WO2010062966A2 (en) | 2008-11-26 | 2010-06-03 | The General Hospital Corporation | Methods for inducing mixed chimerism |
| US9089520B2 (en) * | 2010-05-21 | 2015-07-28 | Baylor College Of Medicine | Methods for inducing selective apoptosis |
| EP2651442B1 (en) | 2010-12-14 | 2020-04-22 | University of Maryland, Baltimore | Universal anti-tag chimeric antigen receptor-expressing t cells and methods of treating cancer |
| LT2956175T (lt) * | 2013-02-15 | 2017-12-11 | The Regents Of The University Of California | Chimerinis antigeno receptorius ir jo panaudojimo būdai |
| AU2014225708B2 (en) | 2013-03-05 | 2018-10-18 | Baylor College Of Medicine | Heparanase expression in human T lymphocytes |
| EP3925618A1 (en) | 2013-07-29 | 2021-12-22 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| EP3087101B1 (en) | 2013-12-20 | 2024-06-05 | Novartis AG | Regulatable chimeric antigen receptor |
| GB201405845D0 (en) * | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
| WO2016014553A1 (en) * | 2014-07-21 | 2016-01-28 | Novartis Ag | Sortase synthesized chimeric antigen receptors |
-
2014
- 2014-07-23 EP EP21162954.8A patent/EP3925618A1/en active Pending
- 2014-07-23 EP EP14832043.5A patent/EP3027204B1/en active Active
- 2014-07-23 ES ES14832043T patent/ES2910004T3/es active Active
- 2014-07-23 CA CA2956667A patent/CA2956667A1/en active Pending
- 2014-07-23 WO PCT/US2014/047852 patent/WO2015017214A1/en not_active Ceased
- 2014-07-23 US US14/908,734 patent/US10196444B2/en active Active
- 2014-07-23 JP JP2016531761A patent/JP6543626B2/ja active Active
- 2014-07-23 DK DK14832043.5T patent/DK3027204T3/da active
- 2014-07-23 AU AU2014296626A patent/AU2014296626B2/en active Active
-
2015
- 2015-01-28 US US14/608,098 patent/US10428142B2/en active Active
-
2018
- 2018-12-13 US US16/219,640 patent/US10457731B2/en active Active
-
2019
- 2019-06-06 AU AU2019203955A patent/AU2019203955C1/en active Active
- 2019-06-17 JP JP2019112035A patent/JP2019146598A/ja not_active Withdrawn
- 2019-08-14 US US16/540,673 patent/US20200071399A1/en not_active Abandoned
- 2019-09-17 US US16/573,254 patent/US11530265B2/en active Active
-
2020
- 2020-05-27 JP JP2020092158A patent/JP6748796B1/ja active Active
-
2022
- 2022-11-10 US US18/054,223 patent/US20230287111A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016531567A5 (enExample) | ||
| Klein et al. | The present and future of bispecific antibodies for cancer therapy | |
| Goebeler et al. | Bispecific and multispecific antibodies in oncology: opportunities and challenges | |
| JP7630190B2 (ja) | Ｃｄ７を標的にするヒト化抗体及びその使用 | |
| AU2016343809B2 (en) | Compositions and methods for treatment of cancer | |
| JP2025065142A5 (enExample) | ||
| US20240018251A1 (en) | Bcma-targeting single-domain antibody and use thereof | |
| RU2018135819A (ru) | Иммунные эффекторные клетки с отредактированным геномом | |
| FI3703750T3 (fi) | B-solujen maturaatioantigeenille spesifisiä kimeerisiä antigeenireseptoreita ja koodaavia polynukleotideja | |
| JP2018525006A5 (enExample) | ||
| JP6568239B2 (ja) | Ｔ細胞受容体ライブラリ | |
| JP2015527070A5 (enExample) | ||
| HRP20201906T1 (hr) | Označene kimerne efektorske molekule i njihovi receptori | |
| JP2020517295A5 (enExample) | ||
| JP2019146598A (ja) | 多部分シグナル伝達タンパク質およびその使用 | |
| US20230390336A1 (en) | Chimeric antigen receptor targeting cd7 and use thereof | |
| JP2019518425A5 (enExample) | ||
| FI4063397T3 (fi) | Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi | |
| RU2020135106A (ru) | Векторы экспрессии для химерных рецепторов поглощения, генетически модифицированные клетки-хозяева и их применения | |
| JP2016514462A5 (enExample) | ||
| RU2018109426A (ru) | Химерные антигенные рецепторы со встроенными контролируемыми функциями | |
| JP2024023228A5 (enExample) | ||
| JP2018532432A5 (enExample) | ||
| RU2017121892A (ru) | Клетка | |
| JP2017513478A5 (enExample) |